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A b s t r A c t
The cardiac ryanodine receptor-calcium (Ca2+) release channel type 2 (RyR2) is an 
essential sarcoplasmic reticulum (SR) transmembrane protein that plays a central role 
in excitation-contraction coupling in cardiomyocytes. Aberrant spontaneous, dias-
tolic Ca2+ leak from the SR due to dysfunctional RyR2 is the mechanism underlying 
contractile and relaxation dysfunctions in heart failure. Several potential mechanisms 
have been proposed to explain the dysfunctional RyR2 in heart failure including over-
phosphorylation status of RyR2, altered RyR2 regulation and perturbed RyR2 intra/
intermolecular interactions. Novel therapeutic strategies that enhance myocyte Ca2+ 
homeostasis could prevent and reverse adverse cardiac remodeling and improve clini-
cal outcomes in patients with heart failure.
I n t r o d u c t I o n
Heart failure (HF) is the leading cause of mortality and morbidity in developed 
countries. Despite substantial advances in the treatment, the incidence of HF continues 
to increase after the age of 65, affecting nearly 1 in 100 individuals.1 The search for 
novel therapeutics in HF has led investigators to examine the molecular mechanisms 
underlying HF, to uncover potential therapeutic targets that can slow HF progression, 
improve quality of life and reduce mortality.
Much attention has been given for understanding the role of defects in Ca2+ regula-
tion in HF.2 This is due to the role of Ca2+ as the signal that regulates cardiac muscle 
contraction. Alterations in the excitation-contraction coupling (ECC) may lead to the 
progression of HF and development of lethal arrhythmias. Their common pathophysi-
ologic phenomenon is the “diastolic Ca2+ leak” which involves an aberrant release 
of Ca2+.3 In HF, diastolic Ca2+ leak through ryanodine receptor (RyR) 2 results in a 
decrease in the sarcoplasmic reticulum (SR) Ca2+ content, along with a decrease in 
Ca2+ reuptake by SR Ca2+ -ATPase 2a (SERCA2a) provoking a mismatch in the ECC.4
Defects in every stage of ECC lead to diastolic and systolic abnormalities, as well 
as an increased propensity for ventricular arrhythmias, all of which have been reported 
in patients with HF.5 These defects are the result of altered expression or function of 
proteins that are required for the maintenance of Ca2+ homeostasis. In this review, 
we explain the association between abnormalities in Ca2+ handling in the SR and HF 
and discuss the therapeutic potential of targeting key proteins involved in this process.
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AbbreviAtions
CaMKII = Ca2+/calmodulin-dependent 
protein kinase II
ECC = excitation-contraction coupling
FKBP12.6 (calstabin 2) = FK506 
(tacrolimus) binding protein
HF = heart failure
NCX = Na+/ Ca2+ exchanger
PKA = protein kinase A
PLB = phospholamban
RyR = ryanodine receptor
SERCA = sarcoplasmic reticulum Ca2+ 
-ATPase
SR = sarcoplasmic reticulum
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E X c I t A t I o n - c o n t r A c t I o n  c o u P l I n g
In 1883 Sydney Ringer discovered that Ca2+ is required 
for cardiac contraction.6 Twenty-four years later Locke and 
Roseheim observed that Ca2+ is responsible for the link be-
tween myocardial excitation and contraction.7 Following these 
seminal discoveries, important advances have been made 
toward understanding the molecular determinants of cardiac 
Ca2+ regulation and its role in determining cardiac function. 
In cardiomyocytes, Ca2+ is stored in an intracellular vesicular 
network called sarcoplasmic reticulum (SR).8 Cardiac contrac-
tion can be divided into electrical (excitation) and contractile 
phases. The electrical phase begins with depolarization of the 
sinoatrial node which causes a wave of depolarization to spread 
via the conduction system through the atria and ventricles. On 
the cellular level current flows between a depolarized cardio-
myocyte and its resting neighbor through the gap junctions 
causing depolarization of the membrane potential of the resting 
cell.9 Thereupon, Ca2+ ions passively drawn by a concentration 
and electrochemical gradient enter the cytoplasm and bind to 
the ryanodine receptors (RyR) type 2 that are located on the 
surface of the SR and trigger the release of even bigger amount 
of Ca2+ out of the SR. This process termed Ca2+ induced Ca2+ 
release, raises the cytosolic [Ca2+] about 10-fold to 1μM and 
initiates the ECC. The Ca2+ binds then to troponin C, which 
causes a conformational change exposing binding sites for 
myosin on the actin filaments. Myosin forms crossbridges with 
actin, shortening thus the sarcomere and causing cardiac muscle 
contraction.1 Calcium is then pumped back into the SR by the 
sarcoplasmic/endoplasmic reticulum ATPase (SERCA 2a) and 
exchanged across the plasma membrane for Na+ by the Na+/ 
Ca2+ exchanger, lowering the cytosolic [Ca2+] to baseline of 
100 nM, thereby causing relaxation.11
s t r u c t u r E  A n d  f u n c t I o n  o f 
r y A n o d I n E  r E c E P t o r s  I n  n o r m A l 
h E A r t
Ryanodine receptors are the largest ion channels known 
in literature. They are key components of the excitation-
contraction coupling.12 They were originally identified using 
the plant alkaloid ryanodine, isolated from Ryania speciosa 
found in Central and South America. At that time, ryanodine 
was being tested as a potential pesticide13 due to its paralyzing 
effect on insects.14 Ryanodine was subsequently found to induce 
profound paralysis of cardiac and skeletal muscle (Figure 1).15
Ryanodine was used as a high affinity ligand to track 
the purification of its receptor from sarcoplasmic reticulum 
preparations. The purified ryanodine receptors were shown to 
be Ca2+ release channels in skeletal and cardiac muscles.16,17 
Ryanodine was shown to lock the channel open in a charac-
teristic sub-conductance state resulting in a SR Ca2+ leak that 
provided a mechanism for the paralytic action of the drug.18
There are 3 RyR isoforms in mammals. RyR1 is predomi-
nant in skeletal muscle.19 RyR3 was first cloned from rabbit 
brain.20 It is more widely distributed and is expressed not only 
fIgurE 1.
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in the brain but also in skeletal muscle, diaphragm and many 
other organs.20 The cardiac ryanodine receptor isoform RyR2, 
is a homotetramer comprising four 565KDa monomers. Each 
monomer contains a transmembrane segment located at the 
carboxyterminus that is formed by 10% of the linear sequence, 
whereas the remaining 90% of the protein sequence encodes 
an enormous cytoplasmic domain that serves as a scaffold for 
regulatory subunits and enzymes that modulate the function 
of the channel.21
During the action potential, Ca2+ entry through the L-type 
calcium channels triggers synchronized openings of RyR2 
allowing a rapid and transient release of Ca2+ from the SR.21 
The subsequent intracellular Ca2+ elevation triggers myocytes 
to contract. Relaxation occurs when RyR2 closes, Ca2+ dis-
sociates from C-Troponin and is mainly taken back into the 
SR by SERCA 2a and partially extruded by the Na+/Ca2+ 
exchanger (NCX).
The amount of Ca2+ released by the SR during a cardiac 
cycle depends on the L-type Ca2+ channel, the RyR2 Ca2+ 
sensitivity and the SR Ca2+ load. Activation of RyR2 is highly 
sensitive to Ca2+ concentration and intracellular Ca2+ is the 
main modulator of RyR2 function in the heart. To date, the 
mechanism responsible for local Ca2+ release termination 
remains unclear.22 RyR2 opening probability (Po) is regu-
lated by other endogenous factors such as Mg2+ ions, ATP, 
pH and redox state.23,24 Furthermore, on its large N-terminal 
cytosolic side, RyR2 is associated and regulated by several 
proteins including FK-506 (tacrolimus) binding protein 12.6 
(FKBP12.6 also called calstabin2), calmodulin, protein kinase 
A, calmodulin kinase II, phosphatase 1, phosphatase 2A and 
phosphodiesterase 4D3.25-29 These proteins control RyR2 
stability, Ca2+ sensitivity and Po.
From the luminal side, RyR2 are directly linked to triadin, 
junctin and calcineurin.30 These proteins sense SR Ca2+ con-
tent especially through their interactions with calsequestrin 
which affects RyR2 channel gating.31 Independently of the 
classical Ca2+-induced Ca2+ release mechanism, spontaneous 
Ca2+ release may occur when SR Ca2+ load reaches a certain 
threshold. This process also called store-overload-induced 
Ca2+ release generates cytosolic Ca2+ waves and subsequent 
delayed after depolarization. Mutation of the RyR2 or the 
associated proteins on the luminal side may affect intra store 
Ca2+ sensitivity and reduced store-overload-induced Ca2+ 
release threshold (Figure 2).
m E c h A n I s m s  o f  r y r 2 
d y s r E g u l A t I o n  I n  h E A r t  f A I l u r E
Over the past 10 years, the role of pathological diastolic 
Ca2+ leak through dysfunctional RyR2 has been recognized 
as an important contributor to the progression of the heart 
failure.27 The heart failure RyR2 Ca2+ leak hypothesis was 
that the chronic hyperadrenergic state observed in HF patients 
induced chronic protein kinase A (PKA) hyperphosphorylation 
of RyR2 at Ser2808, causing depletion of calstabin2 from the 
channel complex.27 The term hyperphosphorylation describes 
RyR2 in which 3-4 of the four RyR2 monomers are chronically 
PKA phosphorylated. PKA hyperphosphorylated/calstabin 
2 depleted channels are sensitized to cytosolic Ca2+ release 
during diastole, referred to as a diastolic SR Ca2+ leak. This 
latter would reduce SR Ca2+ stores and activate transient 
inward current.29
The HF RyR2 Ca2+ leak hypothesis is supported by studies 
demonstrating that HF patients have PKA hyperphosphorylated 
and calstabin 2 depleted RyR2. This hypothesis has been chal-
lenged on the observation that β adrenergic receptor density 
on cardiomyocytes is reduced in HF and that this coincides 
with a global reduction in cytosolic cAMP levels.32 It is unclear 
how the presence of a chronic hyperadrenergic state in HF 
can lead to chronic PKA hyperphosphorylation of RyR2. This 
paradox can be explained by the general remodeling of RyR2 
macromolecular complex and depletion of phosphatases33 that 
occurs in HF. Depletion of phosphatases can induce discrete 
microdomains of elevated levels of cAMP in the vicinity of 
RyR2 and decreased rate of dephosphorylation of a hyper-
phosphorylated channel.29
Alternative mechanisms have been proposed to explain SR 
Ca2+ leak in HF. Disulfide oxidation of free cysteine residues 
on RyR2 increases the sensitivity of the channel to luminal Ca2+ 
in lipid bilayer as well as enhances SR Ca2+ leak, manifested 
by reduced SR Ca2+ load in cardiomyocytes.34 Also the Ca2+/
calmodulin-dependent protein kinase II (CaMKII) levels 
are elevated in human HF samples suggesting that CaMKII 
phosphorylation of RyR2 may contribute to the pathogenesis 
of HF.35 This hypothesis is supported by reports that there is 
an increase in CaMKII-dependent phosphorylation of RyR2 
in HF, which enhances SR Ca2+ leak.36
fIgurE 2.
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A r r h y t h m I A s  d u E  t o  A b n o r m A l 
r y r 2  f u n c t I o n
There is sufficient evidence, particularly from experimen-
tal models to suggest that RyR2 function in HF is perturbed 
and that diastolic leak is a feature of HF even if there is no 
agreement on the precise mechanism of dysfunction. These 
changes in RyR2 function in HF take place against a greatly 
modified cellular landscape which could also contribute to 
the propensity for arrhythmia. The close spatial relationship 
between T-tubule and junctional SR-the dyadic cleft- which is 
also important to the electrophysiological homeostasis of the 
heart beat can become disrupted in HF.37,38 Co-localisation 
between RyR2 and L type calcium channel is disturbed as T-
Tubules are lost from the Z-line positions leaving junctional 
RyR2 ”orphaned”.38 This will have serious repercussions for the 
critical interplay between RyR2 activation of L-type calcium 
channel (from RyR2 Ca2+ release).39
Action potential duration is increased in human HF. Elec-
trical remodeling and down regulation of K+ channels occurs 
early in the development of hypertrophy.40,41 However, L-type 
calcium channel protein expression itself in most studies is 
unchanged in HF.41 Many studies show upregulation of NCX 
expression two or three fold. 42 The inward rectifying K+ cur-
rent normally stabilizes the resting potential of the membrane 
but its activity is reduced by Ca2+. The increased diastolic leak 
of Ca2+ in HF may contribute to destabilization of the resting 
potential and together with the increase in NCX could lower 
the threshold for delayed after-depolarizations so that even a 
modest diastolic leak from RyR2 may result in an increased 
propensity to trigger a fatal arrhythmia.43
r y A n o d I n E  r E c E P t o r  A s  A  n E W 
t h E r A P E u t I c  t A r g E t  o f  h E A r t 
f A I l u r E
In the past few years, a considerable amount of new infor-
mation has been made available with regard to the molecular 
mechanism of abnormal Ca2+ handling in HF. Because the 
alteration of RyR2 plays a key role in the defective, intracel-
lular Ca2+ handling in HF, it is logical to consider the RyR2 
as a promising therapeutic target of HF. In HF, the myocyte, 
because of the increased levels of circulating catecholamines, 
has already compensated by reducing β-receptor number.44 
However, these compensatory mechanisms result in a unco-
ordinated state of phosphorylation as regards ECC proteins, 
with hypophosphorylation of phospholamban (PLB)45 and 
hyperphosphorylation of RyR2.46 The long term effect of 
β-blockade has broad spectrum consequences on ECC by 
increasing phosphorylation of PLB, hence increasing SERCA 
activity and elevating SR Ca2+ store concentrations.47
RyR2 hyperphosphorylation is reported to be reduced 
and FKBP12.6 binding levels restored in a paced dog model 
treated with propranolol48 and in human heart muscle strips 
treated with carvedilol, metoprolol or atenolol.49 The AT1 
receptor antagonist, valsartan, which inhibits noradrenaline 
release from the synaptic pool, also restores SR function by 
reducing Ca2+ leak.50 There is evidence that patients prescribed 
the β-blocker carvedilol had improved clinical outcomes in 
HF.51 Animal studies with carvedilol suggest its additional 
effectiveness might be attributed to its antioxidant properties 
and stimulation of SERCA gene transcription,52 implicating a 
new protective role of the drug through molecular alterations.
s t A b I l I z I n g  r y A n o d I n E  r E c E P t o r 
t y P E  2  A c t I V I t y
Improvements in knowledge of Ca2+ dynamics have led to 
increased understanding of the therapeutic potential of target-
ing Ca2+handling proteins. Thus, a number of pharmacological 
and gene therapy strategies aimed at restoring the function of 
the sarcoplasmic reticulum by preventing Ca2+ leakage have 
been investigated.
Pharmacological strategies aimed at reducing Ca2+ leak-
age through RyR2 involve the use of agents that interact with 
RyR2 and inhibit Ca2+ release from the SR, either by altering 
the gating of RyR2 channel or controlling into translocation. 
Unfortunately, most of the cloning RyR2-targeting drugs, such 
as dantrolene and flecainide have unacceptable adverse effects 
or lack of long term efficacy.53
JTV-519 (K201) is a promising new drug with cardioprotec-
tive effects.54 It is a 1-4- benzothiazepine drug and a nonspecific 
blocker of Na+, K+ and Ca2+ channels with antiarrhythmic 
properties.55 Like diltiazem, JTV 519 blocks the L-type calcium 
current, but it is not classified as a Ca2+-channel blocker.55 It is a 
relatively nonselective blocker of cation currents, including the 
Na+ current in a voltage-dependant and frequency-dependant 
manner.56 It also blocks the inward rectifying K+ current and 
rapidly activating component of the delayed rectified K+ cur-
rent but not the slowly activating component.57
JTV-519 stabilizes the closed state of RyR2 and increases 
the binding affinity of FKBP12.6 for RyR2, thereby reducing 
and preventing Ca2+ leak and protecting against ventricular 
arrhythmia, contractile dysfunction and Ca2+ overload.55,58 This 
beneficial combination of activity dramatically ameliorates the 
progression of HF as a result of myocardial damage from Ca2+ 
overload. The most recent evidence shows that JVT519 protects 
against Ca2+ leak from the SR independent of the interaction 
between FKBP12.6 and RyR2.59 Thus, stabilization of RyR2 
reduced detrimental intracellular Ca2+ leak and improves 
both diastolic and systolic contractile function in the human 
heart with or without FKBP12.6-RyR2 binding interaction. 59
Rycals (CPU0213, S107 and S44121) are drugs that sta-
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bilize RyR2-FKBP12.6 complexes and inhibit Ca2+ leakage 
from the sarcoplasmic reticulum; they could therefore also 
have beneficial effects in patients with heart failure.60 To our 
knowledge, cardioprotective effects of Rycal drugs have not 
yet been shown. However, the efficacy of S44121 is currently 
being evaluated in patients with chronic HF who are at risk 
for ventricular arrhythmias.61
Another potential target for HF therapy is the RyR2-
stabilizing protein S100A1. Reduced S100A1 expression has 
been implicated in cardiomyopathies62 and animal models have 
shown the potential of S100A1 gene therapy for treatment 
of HF.63 The safety and efficacy of coronary venous S100A1 
delivery has been shown in a pig model of post-ischemic heart 
failure; contractile function and cardiac remodeling were sig-
nificantly improved.64 However, this system has not yet been 
evaluated in human HF.
c o n c l u s I o n
An increasing body of evidence in the literature suggests 
that alteration of the properties of the Ca2+ release complex 
consisting of RyR2 and its satellite proteins (particularly 
FKBP12.6 or calstabin2) is the key element to understand the 
pathogenic mechanism of HF. An abnormally high level of 
PKA-mediated phosphorylation of RyR2 and the dissociation 
of one of the satellite proteins of RyR2, FKBP12.6 (calstabin2), 
are recognized in some cardiac disease models and regarded 
as important factors related to the mechanism of pathogen-
esis. This view is supported by the fact that beta-blockers and 
angiotensin receptor blockers (ARB) (suppressors of PKA 
phosphorylation) appear to prevent severe disease complica-
tions from occurring. However, many researchers have observed 
no change in phosphorylation and FKBP12.6 (calstabin2) 
in similar condition; this might suggest that the abnormal 
properties of phosphorylation and FKBP12.6 (calstabin2) 
are manifested in particular stages of disease development or 
under particular conditions.
As various complications linked with pathogenic processes 
have begun to be resolved at a molecular level, we now have a 
better chance to hunt for potentially useful therapeutic agents. 
Of particular interest in this context is the recent finding 
that JTV519, the drug that has been known to prevent Ca2+ 
overload and related complications, prevents those abnormal 
changes in the properties of the RyR2, such as interdomain 
interactions, PKA phosphorylation and the RyR2 bound 
FKBP12.6 (calstabin2). This new form of therapy targeting 
the Ca2+ regulatory protein should open up a new chapter for 
the future development of methods for the prevention and 
treatment of HF.
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